Status:
COMPLETED
Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Lead Sponsor:
Siami, Paul F., M.D.
Collaborating Sponsors:
GlaxoSmithKline
Pfizer
Conditions:
Benign Prostatic Hyperplasia (BPH)
Eligibility:
MALE
50+ years
Phase:
PHASE4
Brief Summary
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride given for 18 months, including a 1-year double-blind randomized co-administration with either tolterodine ER...
Detailed Description
Men who are treated with an alpha blocker (AB) or 5-alpha reductase inhibitor (5-ARI) for benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS) often have symptoms including urina...
Eligibility Criteria
Inclusion
- This subject population will consist of males ≥ 50 years of age who have lower urinary tract symptoms (LUTS) due to benign prostatic enlargement (BPE) for a minimum of 3 months
- Inclusion criteria at screening:
- Subjects who understand and speak English and are able to comply with the protocol, complete the diaries, and other study tools
- Subject has provided written informed consent and HIPAA authorization
- Ambulatory male subjects ≥ 50 years of age
- Able to use the toilet without difficulty
- History of LUTS due to BPE, as diagnosed by history as well as digital rectal exam (DRE), for ≥ 3 months suitable for medical therapy with 5-ARI in combination with antimuscarinic drugs
- Prostate volume (PV) ≥ 30 cc as measured by transrectal ultrasound (TRUS)
- International prostate symptoms score (IPSS) ≥12
- Post Void Residual Volume \< 150 mL at baseline
- Uroflowmetry-Qmax \> 5 mL/sec and ≤ 15 mL/sec
- Prostate specific antigen (PSA) ≥ 1.5 ng/ml and in normal age-adjusted range. For those subjects with an elevated age-adjusted PSA, it is the responsibility of the investigator to take standard of care measures to assure reasonable absence of prostate cancer
- Have an average of ≥ 8 micturitions per 24 hrs
- Have an average of 2 episodes of urgency per 24 hrs (defined as those with the Urinary Sensation Scale rating of 3 or more)
Exclusion
- Concurrent use of 5-ARI therapy within the past 3 months
- Concurrent use of alpha blockers within the past 2 weeks
- Concurrent use of antimuscarinics within the past 4 weeks
- Concurrent use of Phosphodiesterase type 5 (PDE-5) inhibitors on a daily basis
- Evidence of chronic inflammation such as interstitial cystitis and bladder stones.
- Evidence of untreated urethral stricture disease
- Uncontrolled narrow angle glaucoma
- Increased post-void residual volume (PVR) defined as PVR \> 150 mL
- Uroflowmetry-Qmax ≤ 5 mL/sec
- Acute urinary tract infection (UTI). These subjects may be treated and re-screened
- Acute urinary retention (AUR) requiring catheter within the last 3 months
- Previous or planned transurethral resection of the prostate (TURP)
- Minimally invasive surgery (MIS) such as transurethral microwave treatment (TUMT), transurethral needle ablation (TUNA), laser, or other minimally invasive procedures within 12 months. Those patients who in the opinion of the investigator did not respond adequately to MIS and fulfill the inclusion criteria are eligible to participate
- A known diagnosis of prostate cancer.
- A known diagnosis of bladder cancer within 5 years of screening. Those patients with history of non-muscle invasive bladder cancer who have not had a recurrence in the past 5 years are eligible to screen for this study and must maintain continued adequate bladder cancer screening at the discretion of the Investigator
- Renal or hepatic impairment defined as 2.5 x upper limit of normal. Some isolated abnormalities would be left at the discretion of the investigator with always keeping in mind to not pose a hazard to the patient.
- PSA \> 10 ng/mL (if the PSA is greater than 4 ng/mL and less than or equal to 10 ng/mL, subjects may be included at the discretion of the Investigator if the PSA has been stable and the patient has had a prostate biopsy showing no evidence of prostate cancer)
- Known or suspected hypersensitivity to dutasteride or tolterodine ER .
- Participation in a clinical trial involving an investigational drug, within 30 days prior to enrollment.
- History of diagnosed gastrointestinal obstruction disease.
- Myocardial infarction within the past 8 weeks.
- Known or suspected drug and/or alcohol abuse.
- Any clinical condition, which, in the opinion of the Investigator, would not allow safe completion of the study.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00939120
Start Date
July 1 2009
End Date
September 1 2014
Last Update
May 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deaconess Clinic Gateway Health Center
Newburgh, Indiana, United States, 47630